OncoVista Innovative Therapies, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 38

OncoVista Innovative Therapies, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “OncoVista Innovative Therapies, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- OncoVista Innovative Therapies, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of OncoVista Innovative Therapies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of OncoVista Innovative Therapies, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the OncoVista Innovative Therapies, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate OncoVista Innovative Therapies, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of OncoVista Innovative Therapies, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the OncoVista Innovative Therapies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with OncoVista Innovative Therapies, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of OncoVista Innovative Therapies, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
OncoVista Innovative Therapies, Inc. Snapshot
OncoVista Innovative Therapies, Inc. Overview
Key Information
Key Facts
OncoVista Innovative Therapies, Inc. – Research and Development Overview
Key Therapeutic Areas
OncoVista Innovative Therapies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
OncoVista Innovative Therapies, Inc. – Pipeline Products Glance
OncoVista Innovative Therapies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
OncoVista Innovative Therapies, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
OncoVista Innovative Therapies, Inc. – Drug Profiles
Cordycepin + Pentostatin
Product Description
Mechanism of Action
R&D Progress
OVI-123
Product Description
Mechanism of Action
R&D Progress
OVI-237
Product Description
Mechanism of Action
R&D Progress
OVI-117
Product Description
Mechanism of Action
R&D Progress
Tubulin Isotype-Specific Anti-miotics
Product Description
Mechanism of Action
R&D Progress
OncoVista Innovative Therapies, Inc. – Pipeline Analysis
OncoVista Innovative Therapies, Inc. – Pipeline Products by Therapeutic Class
OncoVista Innovative Therapies, Inc. Pipeline Products By Target
OncoVista Innovative Therapies, Inc. – Pipeline Products by Route of Administration
OncoVista Innovative Therapies, Inc. – Pipeline Products by Molecule Type
OncoVista Innovative Therapies, Inc. – Company Statement
OncoVista Innovative Therapies, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Financial Deals Landscape
OncoVista Innovative Therapies, Inc., Deals Volume Summary, 2004 to YTD 2010
OncoVista Innovative Therapies, Inc., Deals Summary By Region, 2004 to YTD 2010
OncoVista Innovative Therapies, Inc., Deals Summary, 2004 to YTD 2010
OncoVista Innovative Therapies, Inc. Detailed Deal Summary
Acquisition
OncoVista Innovative Therapies Increases Stake In AdnaGen
OncoVista Acquires Additional Stake In AdnaGen
Aviation Upgrade Technologies Acquires OncoVista
OncoVista Innovative Therapies Acquires Controlling Stake In AdnaGen
Equity Offering
OncoVista Innovative Therapies Completes Private Placement Of $7 Million
OncoVista Innovative Therapies Enters Into Agreement With AdnaGen And The University of Texas M. D. Anderson Cancer Center
Licensing Agreements
OncoVista Innovative Therapies Enters Into Licensing Agreement With OSI Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Private Tutoring - Global Strategic Business Report
• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Education Services - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Library Use of Video & Audio, 2011-2012 Edition
• International Military and Civilian Unmanned Aerial Vehicle Survey
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report